Novartis Beats Q2 Sales and Profit Estimates, Posts $14.41 Billion in Revenue as Newer Drugs Offset Entresto Decline
Novartis reported second-quarter net sales of $14.41B and core earnings per share of $2.41, surpassing analyst estimates and driving a 3% year-over-year increase in revenue.
Strong sales in newer cancer medicines offset declining revenue for Entresto, which faced generic competition. The company reaffirmed its full-year guidance for low single-digit sales growth and cited European regulatory approvals for multiple pipeline products.
From the sources (3 posts)
@firstsquawkNovartis Q2 2026 Earnings - Net Sales $14.41B (est $13.94B) - Core EPS $2.41 (est $2.16) - Promacta/Revolade Sales $179M (est $202.1M) - Tasigna Sales $142M (est $147.2M) - Kisqali Sales $1.70B (est $1.68B) - Pluvicto Sales $651M (est
@businessNovartis reports higher-than-expected profit last quarter as newer cancer medicines offset the aging blockbuster Entresto’s generic hit, signaling a return to growth
@wallstengineNOVARTIS $NVS Q2’26 EARNINGS HIGHLIGHTS 🔹 Revenue: $14.41B (Est. $14.2B) 🟢; +3% YoY 🔹 Core EPS: $2.41 (Est. $2.2) 🟢; flat YoY 🔹 Core Oper. Margin: 41.2%; -100 bps YoY 🔹 FCF: $5.56B; -12% YoY Reaffirms FY26 Guide: 🔹 Sales Growth: Low singl